PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Latest Episodes:

Vivek Subbiah, MD - Seek and You Will Find in Advanced GI Cancers: Identifying and Targeting Uncommon but Actionable Genomic Alterations in Colorectal, Pancreatic, and Other Cancers Mar 01, 2023

Show notes

Go online to PeerView.com/PCK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of personalized medicine, treatment of patients with advanced GI cancers has moved beyond a chemotherapy-centric model to one in which effective treatments can be matched to individual patients based on genomic testing results. What do colorectal and pancreatic cancer providers need to know about baseline testing and personalized treatment strategies, including those that target less common genomic mutations causing RET and NTRK alterations? In this activity, based on a recent live symposium, a panel of experts in GI malignancies presents evidence-based guidance on modern diagnostic protocols and the personalized treatment of fusion-driven cancers. With relevant cases framing the discussion, the panel provides foundational knowledge on tumor-agnostic genomic alterations, updates on genomic testing techniques sensitive enough to capture rare alterations, and strategies for integrating targeted agents into treatment plans. Upon completion of this activity, participants should be better able to: Explain current guidelines and evidence related to molecular testing and targeted therapeutics, enabling timely diagnosis, and treatment of gene fusion–driven GI cancers; Implement collaborative, multidisciplinary genomic testing protocols designed to capture less common but actionable molecular alterations in metastatic or locally advanced GI cancers; and Construct safe, individualized treatment plans for patients with advanced GI cancers who present with uncommon genomic alterations

Marwan Sabbagh, MD, FAAN - Gearing Up for Plasma Biomarkers in the Clinic: Real-World Strategies to Facilitate the Timely and Accurate Neuropathological Diagnosis of Alzheimer’s Disease Mar 01, 2023

Show notes

Go online to PeerView.com/DEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people aged 65 years and older and increasing in prevalence as the population ages. Recent advances in disease-modifying therapies have allowed for the possibility of reductions in disease progression and improved patient outcomes. Significant advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. In this activity, based on a recent live event, a panel of expert faculty provide training in the appropriate integration of validated and emerging cerebrospinal fluid (CSF) and plasma biomarkers into the AD diagnostic workup to identify early-stage AD in symptomatic patients. The faculty utilize a case-based approach to model the application and interpretation of fluid biomarkers in clinical practice, as well as highlight advantages and limitations associated with currently available and emerging CSF and plasma biomarkers. Upon completion of this activity, participants should be better able to: Apply validated fluid biomarkers to facilitate a timely neuropathological diagnosis of AD in symptomatic patients; Describe the limitations and advantages associated with currently available and emerging fluid diagnostics; and Integrate emerging plasma biomarkers into the diagnostic workup through appropriate application and accurate interpretation to improve early diagnosis and precision management of AD

Evan S. Dellon, MD, MPH - What's New in the Management of Eosinophilic Esophagitis: Working Together to Integrate Targeted Treatment Options Into Practice Mar 01, 2023

Show notes

Go online to PeerView.com/TGA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Eosinophilic esophagitis (EoE) is a chronic allergic type 2 inflammatory disease characterized by a clinical and pathologic phenotype of progressive esophageal dysfunction due to tissue inflammation and fibrosis. Diagnosis of EoE is frequently missed or delayed, which can lead to such complications as esophageal stricture and reduced patient quality of life. Fortunately, targeted biologic therapies already approved for other type 2 inflammatory disorders are approved, or are in development, for the treatment of EoE and appear promising. This case-based activity will offer expert insights for recognizing and diagnosing EoE, monitoring and managing EoE, and integrating targeted therapies into practice. Upon completion of this activity, participants should be better able to: Diagnose eosinophilic esophagitis (EoE) promptly according to the latest guidelines and criteria to decrease the risk of complications precipitated by uncontrolled disease; Apply the latest clinical research developments and updates in treatment guidelines to the management of EoE in collaboration with the healthcare team; and Select treatment, including novel targeted biologic therapies, for patients with EoE based on the latest clinical evidence

Ghassan Abou-Alfa, MD, MBA - The HCC Revolution Continues: Exploring Evidence-Based Treatment Selection and Sequencing in Advanced Disease and Beyond Mar 01, 2023

Show notes

Go online to PeerView.com/NNK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of patients with hepatocellular carcinoma (HCC) have been nothing short of revolutionary. But what does this revolution in care mean for your patients? In this activity, based on a recent live symposium, a multidisciplinary panel of experts shares best practices for providing personalized medicine that incorporates newer therapy options, including immunotherapy-based combinations in the first-line setting. With discussion of cases drawn from clinical practice, the panel will link the latest data and research to real-world patient care and provide guidance on selecting and sequencing treatments as patients continue to the second line and beyond, and which emerging strategies are set to bring further changes to HCC outcomes. Our panel will also focus on treatment of patients in the early and intermediate stages, including innovative multimodal strategies and the importance of integrating systemic therapy into earlier stages of disease. Upon completion of this activity, participants should be better able to: Summarize clinical evidence on approved and emerging immunotherapy, targeted, antiangiogenic, and combination-based platforms across HCC settings and patient populations; Recommend individualized, evidence-based approaches to treatment selection and sequencing for patients with advanced HCC over multiple lines of therapy; and Develop strategies to improve treatment delivery, tolerability, and safety management for patients with HCC receiving modern therapies

John C. Byrd, MD - Taking the Next Steps With Next-Generation BTK Inhibitors in CLL, MCL, and DLBCL Mar 01, 2023

Show notes

Go online to PeerView.com/EVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with next-generation BTK inhibitors (BTKi) in CLL/SLL, MCL, and DLBCL from the 2022 ASH annual meeting? Find out in this new activity where two experts will interpret new findings supporting the integration of next-generation BTKi across multiple lines of therapy in B-cell cancers, while addressing practical safety considerations that may arise while patients are on therapy; additionally, the experts will provide their takes on how new science will drive future applications of BTKi in a range of B-cell cancer settings. Don’t miss this educational and informative activity! Upon completion of this activity, participants should be better able to: Cite updated evidence with BTKi-based strategies in CLL/SLL, including longer-term follow-up from pivotal trials, current guidelines, head-to-head data, and outcomes with novel BTK combination platforms; Summarize efficacy and safety findings supporting the use of BTKi options in aggressive lymphoma, including in R/R MCL and DLBCL; Select personalized therapy with BTKi in CLL based on current evidence, safety considerations, and patient and disease characteristics; and Integrate BTKi therapy into the management of aggressive lymphoma, including in patients with previously treated MCL or DLBCL

Nasser Altorki, MD, Jonathan D. Spicer, MD, PhD, FRCSC - Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC: How to Modernize Best Practices Based on New Evidence and Better Multidisciplinary Alliances Mar 01, 2023

Show notes

Go online to PeerView.com/YRK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immunotherapy revolution has swiftly expanded from advanced lung cancer to the early-stage, resectable, curative-intent setting, and it is radically transforming the standards of care for stage I-III resectable NSCLC. Immunotherapies are now approved in both adjuvant and neoadjuvant settings, and ongoing trials are expected to propel more immunotherapy-based options into early-stage disease settings as well as clarify the best perioperative approaches. What do these developments mean for thoracic surgeons and other members of the multidisciplinary lung cancer care team? How should best practices and standards of care be modernized? What new workflows need to be established to guide individualized treatment selection and make the most of new immunotherapy options to reduce the risk of recurrence and increase the possibility of cure for more patients? This PeerView educational activity, based on a recent live symposium, brings together top experts to answer these questions. The faculty panel discusses new, practice-changing evidence, implications and applicability of these advances to practice, and how to best facilitate the incorporation of perioperative immunotherapy into new standards of care to improve outcomes and quality of life for patients with resectable NSCLC. Upon completion of this activity, participants should be better able to: Analyze the current evidence supporting the use of neoadjuvant and adjuvant immunotherapy approaches in stage I-III NSCLC, including the biologic and mechanistic rationale, novel endpoints, and data from key clinical trials; Identify patients with resectable NSCLC who are candidates for perioperative immunotherapy; and Implement neoadjuvant and/or adjuvant immunotherapy as part of individualized treatment plans for patients with resectable stage I-III NSCLC based on all the relevant factors, effective multidisciplinary collaboration, and shared decision-making

Marwan Sabbagh, MD, FAAN - Translating the Latest Research Advances Into Routine Care for Alzheimer’s Disease: Preparing Dementia Specialists With the Latest Strategies to Support Early Diagnosis and Comprehensive Care Mar 01, 2023

Show notes

Go online to PeerView.com/GAZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses strategies for optimizing the biomarker-based diagnosis of Alzheimer’s disease early in the disease course and the selection of appropriate patients who might benefit from novel disease-modifying therapies, as well as a comprehensive care model for the multidisciplinary management of patients with Alzheimer’s disease. Upon completion of this activity, participants should be better able to: Apply current and emerging diagnostic tools to optimize the biomarker-based diagnosis of AD early in the disease course; Select appropriate patients with AD who may benefit from novel disease-modifying therapies based on an understanding of their mechanisms of action, efficacy, and safety profiles; and Utilize a comprehensive care model to optimize the multidisciplinary management of patients with AD

April W. Armstrong, MD, MPH - Understanding TYK2’s Role in Psoriasis Pathogenesis and Taking a Practical Approach to Realizing Its Potential in the Clinic Mar 01, 2023

Show notes

Go online to PeerView.com/XMX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Psoriasis, a chronic inflammatory disease that affects up to 1 in 20 people worldwide, can drastically impact a patient's quality of life and health. The number of therapies for patients with moderate-to-severe psoriasis has grown steadily over the past 2 decades. Biologic immunotherapies have been the primary agents to gain approval, while small-molecule therapies have lagged in development. Deucravacitinib is a newly approved oral small molecule that inhibits the activity of TYK2, a member of the JAK family. Deucravacitinib allosterically inhibits TYK2 activity by binding to the regulatory domain rather than the catalytic domain. Binding in this way gives deucravacitinib greater specificity for TYK2 versus the closely related JAK1/2/3. Deucravacitinib has demonstrated safety and efficacy in moderate-to-severe chronic plaque psoriasis in two phase 3 pivotal trials (POETYK PSO-1 and PSO-2). Psoriasis Area Severity Index (PASI) 75 and static Physician's Global Assessment (sPGA) 0/1 response rates were significantly higher with deucravacitinib versus placebo or apremilast. In this activity, based on a recent live symposium, expert faculty discuss the clinical implications of targeting TYK2 in psoriasis, as well as strategies to identify patients for whom inhibition of TYK2 would be an appropriate treatment option based on available data. In addition, the faculty delve into the importance of shared decision-making in formulating personalized management plans for patients with psoriasis. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of moderate-to-severe psoriasis as it relates to selective targeting of TYK2; Identify patients with psoriasis for whom inhibition of TYK2 would be an appropriate treatment option based on available efficacy and safety data and practice guidelines; and Develop personalized management plans for patients with psoriasis using principles and tools of shared decision-making, empowering patients to participate in treatment decisions and remain adherent to therapies

Nathan A. Pennell, MD, PhD, FASCO - Fine-Tuning Biomarker Testing to Identify and Target RET Fusions as Uncommon But Actionable Genomic Alterations in NSCLC Feb 02, 2023

Show notes

Go online to PeerView.com/JBE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Less common genomic alterations such as gene fusions represent actionable and important therapeutic targets in a substantial proportion of patients with non–small cell lung cancer (NSCLC). Although they are relatively rare, it is essential to conduct appropriate biomarker testing to identify these alterations because highly effective targeted therapies have become available that can significantly improve patient outcomes versus older targeted therapies or cytotoxic agents. RET fusion–positive NSCLC is one such example. Next-generation, more selective tyrosine kinase inhibitors (TKIs) have demonstrated remarkable efficacy and improved safety in patients with tumors exhibiting RET fusions. However, testing for these fusions and other less common alterations as well as interpreting reports of testing results can be challenging, which can lead to missed opportunities to offer the best possible therapy to patients who could benefit from them. This educational activity is designed to help professionals involved in the testing and treatment of patients with NSCLC develop their knowledge and skills to bridge the current gaps in the care of patients with lung cancer. Expert faculty provide practical guidance on how to select the correct biomarker testing approach and platform to identify gene fusions and other less common alterations in NSCLC, implement the testing in-house or externally, and decipher the results or interpret the information in send-out testing reports. The experts also share tips and case-based examples of effectively collaborating with multidisciplinary and interprofessional colleagues to identify suitable candidates for the latest targeted therapies matched to the results of biomarker testing and, consequently, positively impact the outcomes of these patients. Upon completion of this activity, participants should be better able to: Describe the role of gene fusions and other less common alterations in NSCLC, importance of appropriate biomarker testing to identify patients with these alterations, and clinical evidence supporting the use of matched targeted therapies to optimize patient outcomes; Implement team-based strategies to identify patients with NSCLC for biomarker testing, select appropriate tests to capture all actionable genomic alterations, and interpret testing results to guide treatment selection; Apply the latest evidence and guidelines to individualize targeted therapy for patients with lung cancers harboring uncommon gene fusions and other alterations; and Educate patients about the role of biomarker testing in lung cancer, risks and benefits of targeted therapies, and importance of selecting optimal therapy based on biomarker testing results and patient needs, values, and preferences.

Gerald Appel, MD, PhD - Targeted Complements: Exploring New Horizons Designed to Address Gaps in Treating Complement-Associated Kidney Diseases Feb 02, 2023

Show notes

Go online to PeerView.com/FSW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Explore new horizons in complement-targeted treatments with two leading experts who share fresh insights into the underlying pathophysiology of complement-associated kidney diseases and provide evidence-based guidance on their diagnosis and treatment. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of complement-associated kidney diseases, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets; Differentially diagnose patients with complement-associated kidney diseases in a timely manner using evidence-based tools and strategies; and Describe current and emerging treatments for complement-associated kidney diseases, including data from recent clinical trials.